The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
ConclusionsOur data suggest that lixisenatide has a protective effect on the diabetic retina, most likely due to a combination of neuroprotective, anti-inflammatory and antioxidative effects of lixisenatide on the neurovascular unit.
Source: Acta Diabetologica - Category: Endocrinology Source Type: research
More News: Antidoxidants | Brain | Diabetes | Diabetes Type 2 | Endocrinology | Genetics | Neurology | Study | Vitamin A